About Synlogic (NASDAQ:SYBX)
Synlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also involved in developing discovery-stage product candidates for inborn errors of metabolism, including maple syrup urine disease, isovaleric acidemia, and organic acidemias. It has a collaboration agreement with AbbVie S.à.r.l. to develop synthetic biotic medicines for the treatment of inflammatory bowel diseases; Ginkgo Bioworks to discover new living medicines to treat neurological and liver disorders. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SYBX
CUSIPN/A
Phone617-401-9975
Debt
Debt-to-Equity Ratio0.01%
Current Ratio9.82%
Quick Ratio9.82%
Price-To-Earnings
Trailing P/E Ratio-2.24
Forward P/E Ratio-4.55
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.44 million
Price / Sales105.36
Cash FlowN/A
Price / CashN/A
Book Value$3.97 per share
Price / Book3.31
Profitability
EPS (Most Recent Fiscal Year)($5.88)
Net Income$-40,370,000.00
Net MarginsN/A
Return on Equity-50.06%
Return on Assets-45.28%
Miscellaneous
Employees63
Outstanding Shares19,550,000
Synlogic (NASDAQ:SYBX) Frequently Asked Questions
What is Synlogic's stock symbol?
Synlogic trades on the NASDAQ under the ticker symbol "SYBX."
When did Synlogic's stock split? How did Synlogic's stock split work?
Shares of Synlogic reverse split on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.
How were Synlogic's earnings last quarter?
Synlogic (NASDAQ:SYBX) posted its quarterly earnings results on Tuesday, March, 20th. The biotechnology company reported ($0.74) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.07. The biotechnology company had revenue of $0.11 million for the quarter, compared to analysts' expectations of $0.11 million. View Synlogic's Earnings History.
When is Synlogic's next earnings date?
What price target have analysts set for SYBX?
4 Wall Street analysts have issued twelve-month price targets for Synlogic's stock. Their predictions range from $15.00 to $25.00. On average, they anticipate Synlogic's share price to reach $20.00 in the next twelve months. View Analyst Ratings for Synlogic.
What are Wall Street analysts saying about Synlogic stock?
Here are some recent quotes from research analysts about Synlogic stock:
- 1. HC Wainwright analysts commented, "Shares When Financing and Leadership Gaps Filled Stock Data 03/16/2018 Price $1.98 Exchange NASDAQ Price Target $4.00 52-Week High $3.50 52-Week Low $1.60 Enterprise Value (M) $149.2 Market Cap (M) $110 Shares Outstanding (M) 55.9 3 Month Avg Volume 501,177 Short Interest (M) 2.74 Balance Sheet Metrics Cash (M) $21.2 Total Debt (M) $60.0 Total Cash/Share $0.38 EPS Diluted Full Year – Dec 2017A 2018E 2019E 1Q 0.91 (0.22) — 2Q (0.23) (0.18) — 3Q (0.18) (0.17) — 4Q (0.29) (0.16) — FY 0.21 (0.73) (0.39) Revenue ($M) Full Year – Dec 2017A 2018E 2019E 1Q 29.5 10.6 — 2Q 8.7 11.9 — 3Q 11.3 13.1 — 4Q 12.5 14.6 — FY 62.0 50.2 73.3 4 3.5 3 2.5 2 1.5 MAR- 17 J UL- 17 NOV- 17 MAR- 18 4 3 2 1 0 Vol. (mil) Price Another solid Belbuca growth quarter; expect near-term CEO and recapitalization." (3/19/2018)
- 2. According to Zacks Investment Research, "Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The company's pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases such as Urea Cycle Disorder and Phenylketonuria. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other diseases, such as liver disease, inflammatory and immune disorders and cancer. It is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease. Synlogic Inc., formerly known as Mirna Therapeutics Inc., is based in Cambridge, Massachusetts. " (1/31/2018)
Are investors shorting Synlogic?
Synlogic saw a decline in short interest in the month of April. As of April 13th, there was short interest totalling 539,697 shares, a decline of 43.5% from the March 30th total of 955,244 shares. Based on an average daily trading volume, of 96,890 shares, the short-interest ratio is presently 5.6 days. Approximately 4.0% of the company's stock are sold short.
Who are some of Synlogic's key competitors?
Some companies that are related to Synlogic include Athenex (ATNX), Intra-Cellular Therapies (ITCI), CytomX Therapeutics (CTMX), MacroGenics (MGNX), Biohaven Pharmaceutical (BHVN), Flexion Therapeutics (FLXN), Uniqure (QURE), Epizyme (EPZM), Amphastar Pharmaceuticals (AMPH), Inflarx (IFRX), Assembly Biosciences (ASMB), Zai Lab (ZLAB), Alder BioPharmaceuticals (ALDR), Access Pharmaceuticals (ABEO) and Lexicon Pharmaceuticals (LXRX).
Who are Synlogic's key executives?
Synlogic's management team includes the folowing people:
- Dr. José Carlos Gutierrez-Ramos, Pres, CEO & Director
- Mr. Paul Francis Miller Ph.D., Chief Scientific Officer
- Dr. Aoife M. Brennan MB, BCh, BAO, MMSc, Chief Medical Officer
- Prof. Timothy K. Lu, Co-Founder
- Dr. Dean A. Falb Ph.D., Co-Founder & CTO (Age 51)
Has Synlogic been receiving favorable news coverage?
News coverage about SYBX stock has been trending somewhat positive on Thursday, Accern Sentiment reports. Accern rates the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Synlogic earned a news impact score of 0.04 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 47.23 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of Synlogic?
Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Synlogic's stock price today?
One share of SYBX stock can currently be purchased for approximately $13.15.
How big of a company is Synlogic?
Synlogic has a market capitalization of $255.55 million and generates $2.44 million in revenue each year. The biotechnology company earns $-40,370,000.00 in net income (profit) each year or ($5.88) on an earnings per share basis. Synlogic employs 63 workers across the globe.
How can I contact Synlogic?
Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected]
MarketBeat Community Rating for Synlogic (SYBX)
MarketBeat's community ratings are surveys of what our community members think about Synlogic and other stocks. Vote "Outperform" if you believe SYBX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYBX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Synlogic (NASDAQ:SYBX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Synlogic in the last 12 months. Their average twelve-month price target is $20.00, suggesting that the stock has a possible upside of 52.09%. The high price target for SYBX is $25.00 and the low price target for SYBX is $15.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Hold |
| Consensus Rating Score: | 3.00 | 2.80 | 2.67 | 2.33 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $20.00 | $19.00 | $19.6667 | $19.50 |
| Price Target Upside: | 52.09% upside | 93.68% upside | 93.38% upside | 4.11% upside |
Synlogic (NASDAQ:SYBX) Consensus Price Target History
Synlogic (NASDAQ:SYBX) Analyst Ratings History
Show:
(Data available from 4/26/2016 forward)
Synlogic (NASDAQ:SYBX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Synlogic (NASDAQ SYBX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 18.60%
Institutional Ownership Percentage: 55.53%
Synlogic (NASDAQ SYBX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/1/2016 | Jon Irvin | VP | Sell | 280 | $1.43 | $400.40 | 7,625 |  |
| 11/1/2016 | Jon Irvin | VP | Sell | 280 | $1.28 | $358.40 | 8,055 | |
| 10/11/2016 | Jon Irvin | VP | Sell | 150 | $1.83 | $274.50 | 8,335 | |
| 10/3/2016 | Jon Irvin | VP | Sell | 250 | $1.93 | $482.50 | 8,485 | |
| 10/6/2015 | Michael Powell | Director | Buy | 857,142 | $7.00 | $5,999,994.00 | | |
| 10/6/2015 | Pfizer Inc | major shareholder | Buy | 714,285 | $7.00 | $4,999,995.00 | 2,489,364 | |
(Data available from 1/1/2013 forward)
Synlogic (NASDAQ SYBX) News Headlines
| Source: |
|
Synlogic (NASDAQ:SYBX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Synlogic (NASDAQ:SYBX) Income Statement, Balance Sheet and Cash Flow Statement
Synlogic (NASDAQ SYBX) Stock Chart for Thursday, April, 26, 2018
Loading chart…
